CBX 10913
Latest Information Update: 07 Jan 2004
Price :
$50 *
At a glance
- Originator Ciblex Corporation
- Class Anti-inflammatories; Antirheumatics; Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation; Rheumatoid arthritis
Most Recent Events
- 07 Jan 2004 No development reported - Preclinical for Inflammation in USA (PO)
- 07 Jan 2004 No development reported - Preclinical for Rheumatoid arthritis in USA (PO)
- 01 Jun 2000 New profile